2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Melanoma
105
Carcinoma, Renal Cell
38
Leukemia, Myeloid, Acute
36
Neoplasm Metastasis
31
Neoplasms
22
Breast Neoplasms
22
Lymphoma, Non-Hodgkin
21
Kidney Neoplasms
20
Leukemia
18
Carcinoma, Non-Small-Cell Lung
18
Skin Neoplasms
17
Neuroblastoma
17
Ovarian Neoplasms
16
Colorectal Neoplasms
16
Recurrence
14
Leukemia, Lymphocytic, Chronic, B-Cell
14
Lymphoma
13
Myelodysplastic Syndromes
10
Uveal Melanoma
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, Follicular
9
Head and Neck Neoplasms
9
Uterine Cervical Neoplasms
8
Multiple Myeloma
8
Congenital Abnormalities
8
Triple Negative Breast Neoplasms
7
Stomach Neoplasms
7
Lung Neoplasms
7
Hodgkin Disease
7
Squamous Cell Carcinoma of Head and Neck
6
Interventions
Amifostine
19
Cisplatin
15
Radiotherapy
13
Etoposide
10
Cyclophosphamide
9
Carboplatin
8
Paclitaxel
7
Filgrastim
7
Drug Therapy
5
Cytarabine
5
apatinib
4
Methotrexate
4
sodium thiosulfate
3
Methylprednisolone
3
Gemcitabine
3
Docetaxel
3
sargramostim
2
pegfilgrastim
2
glucarpidase
2
etoposide phosphate
2
denileukin diftitox
2
camrelizumab
2
Voriconazole
2
Vincristine
2
Social Determinants of Health
2
Pyridoxine
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Mitoxantrone
2
Melphalan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Drug-Related Side Effects and Adverse Reactions
×
Interleukin-2
×
Clear all
NCT06302062
2024-12-03
TAL-T
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
Recruiting
23 enrolled